Will CV Biomarkers Cull the Middle-Risk People?
Will CV Biomarkers Cull the Middle-Risk People?
Henry R. Black, MD: Hi. I'm Dr. Henry Black. I'm an Adjunct Clinical Professor of Medicine at the Langone NYU School of Medicine, and I'm here with my friend and colleague, Dr. Howard Weintraub.
Howard S. Weintraub, MD: Hi, Henry. I'm Howard Weintraub. I'm the Clinical Director of the NYU Center for the Prevention of Cardiovascular Disease, and Clinical Professor of Medicine at the NYU Langone School of Medicine.
Dr. Black: We've been talking about many areas in regard to how you treat hyperlipidemic patients. I'm interested in workup and evaluation.
Dr. Weintraub: I am very worried about what is going to happen when the individuals who are not part of the cardiovascular population -- [who are] in their late 20s, 30s, and 40s and who are fatter, more likely to develop diabetes and hypertension, and hence coronary disease, cardiac disease -- enter the healthcare arena. It was not budgeted for this, because then they were looking at the usual attributable risk population, which are men in their 60s and 70s and women in their 70s. The healthcare system is going to be taken to its knees because it will have younger people who are going to require more aggressive treatments (which is a synonym for the more expensive treatments, and appropriately so), with drugs and procedures and ER visits and stress tests and nuclear studies and other things that are mandatory.
Henry R. Black, MD: Hi. I'm Dr. Henry Black. I'm an Adjunct Clinical Professor of Medicine at the Langone NYU School of Medicine, and I'm here with my friend and colleague, Dr. Howard Weintraub.
Howard S. Weintraub, MD: Hi, Henry. I'm Howard Weintraub. I'm the Clinical Director of the NYU Center for the Prevention of Cardiovascular Disease, and Clinical Professor of Medicine at the NYU Langone School of Medicine.
Dr. Black: We've been talking about many areas in regard to how you treat hyperlipidemic patients. I'm interested in workup and evaluation.
Dr. Weintraub: I am very worried about what is going to happen when the individuals who are not part of the cardiovascular population -- [who are] in their late 20s, 30s, and 40s and who are fatter, more likely to develop diabetes and hypertension, and hence coronary disease, cardiac disease -- enter the healthcare arena. It was not budgeted for this, because then they were looking at the usual attributable risk population, which are men in their 60s and 70s and women in their 70s. The healthcare system is going to be taken to its knees because it will have younger people who are going to require more aggressive treatments (which is a synonym for the more expensive treatments, and appropriately so), with drugs and procedures and ER visits and stress tests and nuclear studies and other things that are mandatory.
Source...